Melanoma: historical context. References | ПРЕЦИЗИОННАЯ ОНКОЛОГИЯ


BRAF targets in melanoma. Biological mechanisms, resistance, and drug discovery. Cancer drug discovery and development. Volume 82. Ed. Ryan J. Sullivan. Springer (2015)

  1. Bodenham DC. A study of 650 observed malignant melanomas in the South-West region. Ann R Coll Surg Engl. 1968;43(4):218–39.
  2. Laennec R. Sur les melanoses. Bull Faculte Med Paris. 1806;1:24–26.
  3. Norris W. Eight cases of melanosis: with pathological and therapeutical remarks on that disease. Longman, Brown, Green, Longmans, and Roberts. 1857.
  4. Cooper S. The first lines of the theory and practice of surgery. 4th American; 7th London edition ed. Vol. 1. 1844. New York: Samuel S and William Wood.
  5. Urteaga O, Pack GT. On the antiquity of melanoma. Cancer. 1966;19(5):607–10.
  6. Davies H, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.
  7. Pollock PM, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33(1):19–20.
  8. . [cited 2014 1/1/14].
  9. Cockburn M, et al. Melanoma underreporting: why does it happen, how big is the problem, and how do we fix it? J Am Acad Dermatol. 2008;59(6):1081–5.
  10. Kopf AW, Rigel DS, Friedman RJ. The rising incidence and mortality rate of malignant melanoma. J Dermatol Surg Oncol. 1982;8(9):760–1.
  11. Criscione VD, Weinstock MA. Melanoma thickness trends in the United States, 1988–2006. J Invest Dermatol. 2010;130(3):793–7.
  12. Jemal A, et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992–2006. J Am Acad Dermatol. 2011;65(5 Suppl 1):S17–25, e1–3.
  13. SEER Stat Fact Sheets: Melanoma of the Skin 2013 April 2013 [cited 2014 1/1/14]. . Accessed 1 Jan 2014.
  14. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ. 2005;331(7515):481.
  15. Levell NJ, et al. Melanoma epidemic: a midsummer night’s dream? Br J Dermatol. 2009;161(3):630–4.
  16. Linos E, et al. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009;129(7):1666–74.
  17. Guy GP, Ekwueme DU. Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer: a systematic review of the literature. Pharmacoeconomics. 29(10):863–74.
  18. Purdue MP, et al. Recent trends in incidence of cutaneous melanoma among US Caucasian young adults. J Invest Dermatol. 2008;128(12):2905–8.
  19. Ekwueme DU, et al. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006. J Am Acad Dermatol. 2011; 65(5 Suppl 1):S133–43.
  20. Guy GP Jr, et al. Melanoma treatment costs: a systematic review of the literature, 1990–2011. Am J Prev Med. 2012;43(5):537–45.
  21. Pleasance ED, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 463(7278):191–6.
  22. Dong L, et al. Melanocyte-stimulating hormone directly enhances UV-Induced DNA repair in keratinocytes by a xeroderma pigmentosum group A-dependent mechanism. Cancer Res. 2010;70(9):3547–56.
  23. Raimondi S, et al. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int J Cancer. 2008;122(12):2753–60.
  24. Cust AE, et al. MC1R genotypes and risk of melanoma before age 40 years: a populationbased case-control-family study. Int J Cancer. 2012;131(3):E269–81.
  25. Landi MT, et al. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst. 2005;97(13):998–1007.
  26. Fargnoli MC, et al. MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol. 2008;128(10):2485–90.
  27. Landi MT, et al. MC1R germline variants confer risk for BRAF-mutant melanoma. Science. 2006;313(5786):521–2.
  28. Petitti DB, et al. Update on the methods of the U.S. Preventive Services Task Force: insufficient evidence. Ann Intern Med. 2009;150(3):199–205.
  29. Katalinic A, et al. Does skin cancer screening save lives?: an observational study comparing trends in melanoma mortality in regions with and without screening. Cancer. 2012;118(21):5395–402.
  30. Waldmann A, et al. Skin cancer screening participation and impact on melanoma incidence in Germany—an observational study on incidence trends in regions with and without population-based screening. Br J Cancer. 2012;106(5):970–4.
  31. Wolff T, Tai E, Miller T. Screening for skin cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;150(3):194–8.
  32. Federman DG, Kravetz JD, Kirsner RS. Skin cancer screening by dermatologists: prevalence and barriers. J Am Acad Dermatol. 2002;46(5):710–4.
  33. Kimball AB, Resneck JS Jr. The US dermatology workforce: a specialty remains in shortage. J Am Acad Dermatol. 2008;59(5):741–5.
  34. Resneck JS Jr, Kimball AB. Who else is providing care in dermatology practices? Trends in the use of nonphysician clinicians. J Am Acad Dermatol. 2008;58(2):211–6.
  35. Resneck J Jr, Kimball AB. The dermatology workforce shortage. J Am Acad Dermatol. 2004;50(1):50–4.
  36. Marghoob AA, et al. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Screening implications. Cancer. 1995;75(2 Suppl):707–14.
  37. Brady MS, et al. Patterns of detection in patients with cutaneous melanoma. Cancer. 2000;89(2):342–7.
  38. McPherson M, et al. Presentation and detection of invasive melanoma in a high-risk population. J Am Acad Dermatol. 2006;54(5):783–92.
  39. Swetter SM, et al. Melanoma in middle-aged and older men: a multi-institutional survey study of factors related to tumor thickness. Arch Dermatol. 2009;145(4):397–404.
  40. Carli P, et al. Dermatologist detection and skin self-examination are associated with thinner melanomas: results from a survey of the Italian multidisciplinary group on melanoma. Arch Dermatol. 2003;139(5):607–12.
  41. Feit NE, Dusza SW, Marghoob AA. Melanomas detected with the aid of total cutaneous photography. Br J Dermatol. 2004;150(4):706–14.
  42. Kittler H, Binder M. Risks and benefits of sequential imaging of melanocytic skin lesions in patients with multiple atypical nevi. Arch Dermatol. 2001;137(12):1590–5.
  43. Kelly JW, et al. A high incidence of melanoma found in patients with multiple dysplastic naevi by photographic surveillance. Med J Aust. 1997;167(4):191–4.
  44. Terushkin V, et al. Use of and beliefs about total body photography and dermatoscopy among US dermatology training programs: an update. J Am Acad Dermatol. 2010;62(5):794–803.
  45. Binder M, et al. Epiluminescence microscopy. A useful tool for the diagnosis of pigmented skin lesions for formally trained dermatologists. Arch Dermatol. 1995;131(3):286–91.
  46. Benelli C, et al. The dermoscopic versus the clinical diagnosis of melanoma. Eur J Dermatol. 1999;9(6):470–6.
  47. Stanganelli I, Serafini M, Bucch L. A cancer-registry-assisted evaluation of the accuracy of digital epiluminescence microscopy associated with clinical examination of pigmented skin lesions. Dermatology. 2000;200(1):11–6.
  48. Lorentzen H, et al. Clinical and dermatoscopic diagnosis of malignant melanoma. Assessed by expert and non-expert groups. Acta Derm Venereol. 1999;79(4):301–4.
  49. Bono A, et al. Melanoma detection. A prospective study comparing diagnosis with the naked eye, dermatoscopy and telespectrophotometry. Dermatology. 2002;205(4):362–6.
  50. Pellacani G, et al. The impact of in vivo reflectance confocal microscopy for the diagnostic accuracy of melanoma and equivocal melanocytic lesions. J Invest Dermatol. 2007;127(12):2759–65.
  51. Langley RG, et al. The diagnostic accuracy of in vivo confocal scanning laser microscopy compared to dermoscopy of benign and malignant melanocytic lesions: a prospective study. Dermatology. 2007;215(4):365–72.
  52. Olsen G. Removal of fascia—cause of more frequent metastases of malignant melanomas of the skin to regional lymph nodes? Cancer. 1964;17:1159–64.
  53. Veronesi U., Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg. 1991;126(4):438–41.
  54. Balch CM, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg. 1993;218(3):262–7. (discussion 267–9).
  55. Cohn-Cedermark G, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8–2.0 mm. Cancer. 2000;89(7):1495–501.
  56. Thomas JM, et al. Excision margins in high-risk malignant melanoma. N Engl J Med. 2004;350(8):757–66.
  57. Khayat D, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer. 2003;97(8):1941–6.
  58. Snow H. Melanotic cancerous disease. Lancet. 1892;2:872–4.
  59. Balch CM, et al. Tumor thickness as a guide to surgical management of clinical stage I melanoma patients. Cancer. 1979;43(3):883–8.
  60. Morton DL, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 370(7):599–609.
  61. Wasif N, et al. Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol. 2011;104(2):111–5.
  62. Nasabzadeh T, Tsai H-T, Tefera E, Venna S, Potosky A, Atkins M, Jang S. Trends and variations in the use of adjuvant immunotherapy for stage III melanoma in the U.S. population. American Society of Clinical Oncology 2013 Annual Meeting 2013. Chicago, IL. (J Clin Oncol).
  63. Veronesi U, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med. 1982;307(15):913–6.
  64. Karakousis CP, Emrich LJ. Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG. J Surg Oncol. 1987;36(4):235–8.
  65. Morton DL, et al. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg. 1974;180(4):635–43.
  66. Czarnetzki BM, et al. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781). Eur J Cancer. 1993;29A(9):1237–42.
  67. Balch CM, et al. A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (Stage I): prognostic factors analysis and preliminary results of immunotherapy. Cancer. 1982;49(6):1079–84.
  68. Quirt IC, et al. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1991;9(5):729–35.
  69. Sondak VK, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol. 2002;20(8):2058–66.
  70. Morton DL, et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg. 2002;236(4):438–48. (discussion 448–9).
  71. Morton DL, Mozzilo N, Thompson JF, et al. For the Malignant Melanoma Active Immunotherapy Trial 3 (MMAIT) investigators. An international, randomized, phase III trial of bacillus Calmette–Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. ASCO Annual Meeting 2007.
  72. Kirkwood JM, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19(9):2370–80.
  73. Kirkwood JM, et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol. 2001;19(5):1430–6.
  74. Eggermont AM, et al. Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. J Clin Oncol. 2013;31(30):3831–7.
  75. Vantomme V, et al. Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother. 2004;27(2):124–35.
  76. Rosenberg SA, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol. 2005;175(9):6169–76.
  77. Creagan ET, et al. Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses. Cancer. 1987;59(3 Suppl):638–46.
  78. Kirkwood JM, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7–17.
  79. Kirkwood JM, et al. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10(5):1670–7.
  80. Kirkwood JM, et al. Highand low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18(12):2444–58.
  81. Mocellin S, et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010;102(7):493–501.
  82. Kirkwood JM, et al. Melanoma in pediatric, adolescent, and young adult patients. Semin Oncol. 2009;36(5):419–31.
  83. Eggermont AM, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol. 2012;30(31):3810–8.
  84. Pectasides D, et al. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol. 2009;27(6):939–44.
  85. Agarwala SS, Lee LE, Flaherty M, et al. Randomized phase III trial of high-dose interferon alfa-2b for 4 weeks induction only in patients with intermediate and high risk melanoma (Intergroup trial E 1697) in 2011 ASCO Annual Meeting. 2011. Chicago, IL. (J Clin Oncol).
  86. Flaherty LE, Moon J, Atkins MB, Tuthill R, Thompson JA, Vetto JT, Haluska FG, Pappo AS, Sosman JA, Redman BG, Ribas A, Kirkwood JM, Sondak VK. Phase III trial of highdose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): an intergroup study of CALGB, COG, ECOG, and SWOG. ASCO annual meeting 2012.
  87. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.
  88. Robert C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26.
  89. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol. 2013;14(2):e60–9.
  90. Atkins MB, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105–16.
  91. Atkins MB, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008;26(35):5748–54.
  92. Bajetta E, et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferonalpha2b in metastatic melanoma. Ann Oncol. 2006;17(4):571–7.
  93. Schwartzentruber DJ, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119–27.
  94. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.
  95. Rosenberg SA, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550–7.
  96. Wolchok JD, et al. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun. 2010;10:9.
  97. Shahabi V, et al. Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunol Immunother. 2012;61(5):733–7.
  98. Wolchok JD, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155–64.
  99. Lawrence DP, Hamid O, McDermott DF. Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastasis (abstract #8523). J Clin Oncol. 2010;28:8523.Wolchok JD, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–20.
  100. Robert C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 364(26):2517–26.
  101. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab I metastatic or locally advanced, unresectable melamelanoma. 2013, European Cancer Congress 2013 Amsterdam, Netherlands.
  102. Hamid O, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–44.
  103. Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.
  104. Sabatino M, Kim-Schulze S, Panelli MC. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol. 2009;27:2645–2652.
  105. Joseph RW, et al. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother. 35(1):66–72.
  106. Sullivan RJ, Hoshida Y, Kwabi C. A single center experience with high-dose IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response (abstract #9003). J Clin Oncol. 2009;27:15S.

[contact-form-7 id=»5168″ title=»Контактная форма 1″]